Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin. Clinical pharmacokinetics.

E Rey1, G Pons, G Olive

  • 1Département de Pharmacologie Périnatale et Pédiatrique, Hôpital Saint-Vincent de Paul, Paris, France.

Clinical Pharmacokinetics
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A deficit in semantic word learning in Huntington's disease.

Neuropsychologia·2025
Same author

Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats.

The journal of prevention of Alzheimer's disease·2022
Same author

Management of anticoagulation in pregnant women with venous thromboembolism: An international survey of clinical practice.

Thrombosis research·2021
Same author

The impact of pre-eclampsia definitions on the identification of adverse outcome risk in hypertensive pregnancy - analyses from the CHIPS trial (Control of Hypertension in Pregnancy Study).

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Beer effects on postprandial digestive symptoms and gastroesophagic physiology.

Neurogastroenterology and motility·2018
Same author

A Quantitative Point-of-Need Assay for the Assessment of Vitamin D<sub>3</sub> Deficiency.

Scientific reports·2017
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Vigabatrin, an antiepileptic drug, is rapidly absorbed and eliminated renally. Its pharmacokinetics are dose-linear, but dosage adjustments are needed for decreased renal clearance, especially in the elderly.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Metabolism

Background:

  • Vigabatrin is a structural analogue of gamma-aminobutyric acid (GABA).
  • It is administered as a racemic mixture, with the S(+) enantiomer being pharmacologically active.
  • Accurate quantification of enantiomers requires gas chromatography-mass spectrometry.

Purpose of the Study:

  • To characterize the pharmacokinetic profile of vigabatrin and its enantiomers.
  • To investigate the influence of food, age, and renal function on vigabatrin disposition.
  • To explore potential drug interactions and provide dosing recommendations.

Main Methods:

  • High-performance liquid chromatography and gas chromatography-mass spectrometry were used for plasma concentration analysis.
  • Pharmacokinetic parameters including absorption, distribution, elimination, and half-life were determined.

Related Experiment Videos

  • Studies included healthy volunteers, epileptic patients, children, and elderly individuals.

    • Main Results:

    • Vigabatrin exhibited rapid absorption, dose-linear pharmacokinetics, and was not affected by food.
    • The drug is not protein-bound, with a volume of distribution of approximately 0.8 L/kg.
    • Renal excretion is the primary elimination route, with enantiomer half-lives around 7.5-8.1 hours. Elderly individuals showed altered pharmacokinetics due to decreased renal clearance.
    • A significant interaction was noted with phenytoin, causing a 20% fall in plasma concentrations.

    Conclusions:

    • Vigabatrin demonstrates predictable pharmacokinetics in adults, but renal function significantly impacts its elimination, necessitating dose adjustments in the elderly.
    • While effective, plasma concentration monitoring may be less critical than for other antiepileptics due to its prolonged action.
    • Pediatric studies suggest similar disposition to adults but potentially lower bioavailability, requiring higher doses.